Bristol Myers Squibb (BMY) announced that the European Medicines Agency (“EMA”) has validated its marketing authorization application (“MAA”) for the next-generation tyrosine kinase inhibitor (“TKI”) repotrectinib.The MAA is seeking approval of the candidate for the treatment for ROS1 TKI-naïve and pretreated adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (“NSCLC”) and TKI-naïve and -pretreated adult and pediatric patients 12 years and older with NTRK-positive lo ...

Proactive公司背景 - Emily Jarvie是一名政治记者，曾在澳大利亚塔斯马尼亚州霍巴特的Australian Community Media工作[2] - Emily Jarvie后来搬到加拿大多伦多，在新兴的致幻剂行业报道商业、法律和科学发展，2022年加入Proactive[2] - Proactive的金融新闻和在线广播团队为全球投资受众提供快速、易于获取、信息丰富且可操作的商业和金融新闻内容[3] - Proactive的新闻团队遍布世界主要的金融和投资中心，在伦敦、纽约、多伦多、温哥华、悉尼和珀斯设有分部和工作室[4] - Proactive是中小市值市场的专家，也让社区了解蓝筹公司、大宗商品和更广泛的投资故事[5] Proactive公司业务 - Proactive团队跨市场提供新闻和独特见解，包括生物技术和制药、矿业和自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动汽车技术[6] - Proactive一直是前瞻性和热情的技术采用者，团队拥有许多年宝贵的专业知识和经验，同时利用技术来协助和增强工作流程[7] - Proactive偶尔会使用自动化和软件工具，包括生成式人工智能，但所有由Proactive发布的内容都是由人类编辑和撰写的，符合内容制作和搜索引擎优化的最佳实践[8]

AUGTYRO治疗效果 - repotrectinib在ROS1阳性非小细胞肺癌(NSCLC)和NTRK阳性实体肿瘤患者中展示出临床意义的反应率，且对脑内转移的反应强劲，安全性良好[2] - 美国食品药品监督管理局(FDA)已经批准Augtyro™ (repotrectinib)用于治疗成人患有局部晚期或转移性ROS1阳性NSCLC的患者[3] AUGTYRO不良反应 - AUGTYRO治疗患者中5%出现高尿酸血症，其中0.9%为3级或4级高尿酸血症[34][35] - AUGTYRO治疗患者中发生骨折的比例为2.3%，骨折部位包括肋骨、脚、脊柱、髋臼、胸骨和踝关节[36][37] - AUGTYRO治疗ROS1阳性非小细胞肺癌和其他实体瘤患者中，最常见的不良反应包括头晕、味觉异常、周围神经病变、便秘、呼吸困难、共济失调、疲劳、认知障碍和恶心[41][42] AUGTYRO安全警示 - AUGTYRO可能对胎儿造成危害，孕妇需注意潜在风险，建议在治疗期间和治疗结束后2个月内使用有效的非激素避孕措施[38][39] - 避免与强或中度CYP3A抑制剂同时使用AUGTYRO，以免增加不良反应发生率和严重程度[44] - AUGTYRO是CYP3A4诱导剂，与激素避孕药同时使用可能降低其疗效，建议女性使用有效的非激素避孕措施[49][50]

Mananya Kaewthawee Bristol-Myers Squibb (NYSE:BMY) is an American pharmaceutical company and one of the leaders in the oncology and cardiovascular markets. Thesis Since the end of 2022, the company's share price has fallen more than 36% before reaching the strong support level that caused a trend reversal in previous years. Before discussing the investment theses that make Bristol-Myers Squibb an attractive investment opportunity, I'd like to highlight the main reasons for the substantial decline in its pri ...

Key PointsBristol Myers Squibb plans to acquire Karuna Therapeutics for $14 billion. The company also expanded its psychiatric and neurological portfolio.It also offered $4.1 billion for cancer drug start-up RayzeBio.5 stocks we like better than Bristol-Myers SquibbBristol Myers Squibb Company NYSE: BMY is on a buying spree, announcing two acquisitions in less than a week. On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc. NASDAQ: KRTX for $330 per share in cash, for a total equ ...

Fusion Pharmaceuticals Inc.’s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday. Bristol Meyers Squibb Co. BMY, -1.61% announced plans Tuesday to acquire Rayze Bio Inc. RYZB, +100.85% for $4.1 billion. Meanwhile Eli Lilly & Co.’s LLY, ...

RayzeBio被Bristol Myers Squibb收购 - RayzeBio将被Bristol Myers Squibb以约41亿美元的全现金交易收购[2] Gracell被AstraZeneca收购 - Gracell将被AstraZeneca以每股2美元的现金收购[3] Daseke被TFI International收购 - Daseke将被TFI International以约11亿美元的全现金交易收购[5] Karuna Therapeutics被Bristol Myers Squibb收购 - Karuna Therapeutics将被Bristol Myers Squibb以约140亿美元的全现金交易收购[6]

收购交易 - 布里斯托尔-迈尔斯斯奎布公司宣布以41亿美元收购RayzeBio公司[1] - RayzeBio股东将获得104%的溢价[1] - RayzeBio股价在周五收盘后的消息后周二交易中翻倍[1] 公司产品线 - RayzeBio正在开发利用放射性粒子杀灭癌细胞的方法[4] - 其当前产品线包括治疗实体肿瘤的项目，包括胃肠胰神经内分泌肿瘤、小细胞肺癌和肝细胞癌[4]

公司收购 - RayzeBio被Bristol Myers Squibb以每股62.50美元的现金收购，总股权价值约为41亿美元[3] - Bristol Myers Squibb通过收购RayzeBio，将在固体肿瘤治疗领域建立存在，并将放射性荷载物定向传递给癌细胞，成为最有前途和增长最快的新治疗模式之一[5] 公司产品 - RayzeBio是一家临床阶段的放射性药物疗法公司，专注于锕系放射性药物疗法，目前的管线项目针对实体肿瘤，包括胃肠胰神经内分泌肿瘤（GEP-NETs）、小细胞肺癌、肝细胞癌等[3] - RayzeBio的主导项目RYZ101正在进行第3期临床试验，针对胃肠胰神经内分泌肿瘤和早期小细胞肺癌的治疗[2] 公司发展 - RayzeBio的平台具有潜在的重要IND引擎，通过利用全球药物开发能力和基础设施，未来将产生多个治疗候选药物[5] - RayzeBio正在印第安纳波利斯建设一家先进的内部制药工厂，预计2024年上半年开始GMP药物生产[9]

PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors. RayzeBio is a clinical-stage radiopharmaceutical ther ...